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ABSTRACT
Objective To explore women’s attitudes towards non-invasive prenatal testing (NIPT) and determine factors
inﬂuencing their decisions around uptake of NIPT.
Method We conducted qualitative interviews to assess knowledge, attitude and deliberation amongst women offered
NIPT in a public health service. In total, 45 women took part in telephone interviews (79% participation rate).
Results Most women could recount the key aspects of NIPT discussed during pre-test counselling but had variable
knowledge aboutDown syndrome. Analysis ofwomen’s attitudes towards undergoingNIPT revealed three dominant factors
they considered when reﬂecting on the test: (1) how NIPT compared with alternative testing options, (2) reﬂections on
coping and (3) moral or religious values. Exploring the deliberative process revealed the different paths women take when
making decisions. For some, it was an extension of the decision to haveDown syndrome screening; some considered it early
on following the booking-in appointment; others made step-wise decisions about NIPT when it became relevant to them.
Conclusion Our ﬁndings support the importance of personalised counselling, whereby women and their partners
have the opportunity to reﬂect on the implications of the test results in the context of their own lives and values. Our
data highlight the inﬂuence of personal circumstances on decision-making. © 2016 The Authors. Prenatal Diagnosis
published by John Wiley & Sons, Ltd.
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INTRODUCTION
Most Western countries have established prenatal screening
programmes for Down syndrome (DS), with ﬁrst trimester
combined DS screening or second trimester serum screening
followed up by invasive testing for women at increased
risk.1–3 This approach to prenatal screening for DS is,
however, rapidly changing following the introduction of
non-invasive prenatal testing (NIPT), which is based on the
analysis of cell-free DNA in maternal plasma and can be used
to screen for DS and major trisomies with detection rates as
high as 99.2% and low false positive rates (0.09%).4 Although
highly accurate, NIPT is still a screening test and requires
invasive testing for conﬁrmation of a positive NIPT result.5
Regardless of the approach to testing, if DS is diagnosed
during pregnancy, women are faced with the difﬁcult decision
to either continue or terminate their pregnancy. As such, it is
vital that women who are offered DS screening are supported
in their decision-making process to facilitate making an
informed choice, a view emphasised by professional bodies in
the UK and USA.3,6 Despite this, research studies have shown
that pregnant women do not always make informed choices
about traditional DS screening.7–10 Moreover, one of the key
concerns associated with the implementation of NIPT in
clinical practice relates to the potential for routinisation and
undermining of informed choice.11–13
One of the most widely used measures of informed choice is
the Multidimensional Measure of Informed Choice (MMIC)
developed by Marteau et al. for women undergoing DSS.14
The MMIC is based on informed choice being deﬁned as one
made with sufﬁcient knowledge, in line with the person’s
values and attitudes to testing and behaviourally implemented.
We have recently developed and validated it to measure
informed choice (the Informed Choice study) amongst women
offered NIPT in our public sector maternity healthcare
system.15 Whilst quantitative measures of informed choice
are valuable, they do not provide an in-depth understanding
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of decision-making.16 Accordingly, the addition of a qualitative
arm to the quantitative assessment of informed choice is
considered ideal.8 We have previously reported the
quantitative work conducted to measure informed choice for
NIPT in which 89% of women were judged to have made an
informed choice.15 Here, we describe the detailed ﬁndings
from our qualitative work.
METHOD
Approval for the NIPT Evaluation Study was obtained from
NHS Research Ethics Committee London – Camden and
Islington (13/LO/0082) in February 2013.
Sample and recruitment
Recruitment into the RAPID NIPT Evaluation Study is
described in detail in the study protocol.17 In brief, women
with a standard DS screening risk >1/1000 were offered NIPT
as a contingent test. Those with a risk of >1/150 were
considered ‘high risk’ and those with a risk of 1/151 to 1/1000
intermediate risk. A consecutive sample of approximately 100
women at each of eight participating centres were invited to
take part in the Informed Choice study which consisted of
two questionnaires [T1 (containing the adapted MMIC) after
accepting or declining NIPT and T2 one month later]. A subset
of T1 responders (with varying MMIC scores, pregnancy
pathways, DS screening risk, NIPT uptake and demographic
backgrounds) were purposively selected to take part in an
interview. In this paper, we report only the ﬁndings from T1
interviews which focused on exploring the different
dimensions of informed choice (knowledge, attitude and
deliberation). The ﬁndings of the interviews at T2 exploring
the impact of the test results and overall reﬂections on NIPT
are reported elsewhere.18
Interviews and data analysis
Following consent, interviews were digitally recorded and
transcribed verbatim. Data analysis was conducted using
thematic analysis19 and facilitated by NVIVO version 10 software
(QSR International, Pty Ltd). Transcripts were read repeatedly
and broken down into small meaningful units of texts (codes).
Codes were generated both deductively (using key topics from
the interview guide) and inductively (themes emerging from
the discussion). The text in each code was then reviewed
allowing for revision, combination or separation of codes.
Revised codes were then clustered to form broader categories
which were then placed under one of the key dimensions of
informed choice (knowledge, attitude, deliberation and
behaviour). Recruitment of interview participants ceased once
saturation had been reached.
FINDINGS
Participant characteristics
Forty-ﬁve women took part in a telephone interview between
December 2013 and September 2014 (79% response rate).
Interviews lasted between 12 and 38min. The sample
characteristics of the participants are described in Table 1.
Thirty-two women (71%) were intermediate risk, and the
majority (n = 39; 87%) had NIPT. Most (n = 33; 73%) were White
or White British and highly educated (n = 32; 71%).
Knowledge
Most women could recount the key aspects of NIPT that were
discussed during pre-test counselling. Testing procedure (that
NIPT was a blood test), the high accuracy rate and the safety
of the test were frequently cited when participants were ﬁrst
asked about their understanding of NIPT, highlighting the
importance placed on these aspects. In around one third of
cases, women had heard of NIPT prior to being invited to take
part in the Evaluation Study, either through friends and family,
or through the media or on the internet.
All the women interviewed were aware that NIPT tested for
Down syndrome. Nevertheless, when asked about their
understanding of the condition, this was found to be variable.
Most participants were aware that the condition was incurable,
and that those affected had learning difﬁculties but only a
Table 1 Participant characteristics
Participant characteristics n = 45
Maternal age – mean; range 36; 23–45
Educational level
No qualiﬁcation 0
GCSE or O level 4
GCE, A level or similar 3
Vocational (BTEC/NVQ/Diploma) 6
Degree level or above 32
Ethnicity
White or White British 33
Asian or Asian British 5
Black or Black British 3
Other ethnic group 3
Mixed 1
Which faith
None 18
Christian 17
Muslim 6
Jewish 3
Other 0
Sikh 0
Hindu 1
Buddhist 0
DSS risk
Medium risk 32
High risk 13
Further testing
NIPT 39
NIPT and invasive testing 3
No further testing 3
DSS, Down syndrome screening; DS, Down syndrome; NIPT, non-invasive prenatal
testing.
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small number were aware that affected individuals could also
have physical health problems. Information about the
condition had been acquired either at school, through the
media or via the information provided at the booking-in
appointment. A small number had experiential knowledge,
such as a family member having Down syndrome or a friend
having a child with the condition.
Whilst the majority of women knew that NIPT also tested for
Edwards and Patau syndrome, the interviews highlighted that
most participants had no knowledge of these conditions prior
to being informed about them either at the booking-in
appointment, or when they were offered NIPT. Most women
recollected that these conditions were much more severe than
Down syndrome.
Although the majority of women demonstrated good
knowledge about NIPT in the interview, some inaccuracies or
misunderstandings became apparent. This included that NIPT
tested for spina biﬁda; that NIPT was 100% accurate; that there
was ‘a 1% chance that the result could be incorrect’, that NIPT
was more accurate than CVS and the turnaround time for NIPT
results was quicker than for invasive testing. In most cases,
these misunderstandings had been addressed and corrected
during pre-test counselling.
Attitudes
We identiﬁed three dominant factors that shaped women’s
attitudes towards NIPT. Frequently, women would consider a
combination of these factors when formulating their decisions
about testing. We also identiﬁed an important sub-theme –
ambivalence towards undergoing NIPT – which occurred in a
minority of cases.
Comparing NIPT to alternative prenatal testing options
Women frequently discussed NIPT in comparison with
undergoing traditional DS screening, saying they found
traditional screening to be difﬁcult to interpret largely because
of the way the results are reported and in one case because the
complexity of the algorithm used to calculate risk was
confusing. NIPT, in contrast, was frequently described as
‘reassuring’ because it was more accurate; the way the result
was reported (as either ‘highly likely’ or ‘highly unlikely’) was
easier to understand, and because the test looked at material
originating from the baby. Thus, for the majority of women,
NIPT enabled them to have reassurance that the baby was
not affected by one of the three main trisomies and reduced
anxiety for the remainder of the pregnancy.
Whilst most women’s attitudes towards DS screening
supported their decision to have NIPT, in a small number of
cases, the opposite occurred. For two women, screening results
were perceived to be sufﬁciently reassuring that there was no
need for follow-up NIPT.
“I was low risk from screening and felt secure with that
result” P54: intermediate risk, declined NIPT
Women also framed their views of NIPT through comparing
it with invasive testing, particularly those women who were
found to be high risk through DS screening. Although they
acknowledged the test was not diagnostic, for most women,
the accuracy rate was considered high enough to deliver ‘a
clear indication’ without risk of miscarriage.
“Its chances of miscarrying are non-existent with this test
and the fact that then we’ll know for sure, well almost
for sure, but I think it will be good enough for us.”
P22: high risk, had NIPT.
Test safety was found to be key. NIPT enabled women to
make decisions based purely on whether they wanted to know
whether the baby had Down syndrome, rather than having to
weigh this up against the fear of miscarriage. The risks of
invasive testing compared with the non-existent risks of NIPT
were therefore pivotal in the decision-making process.
Whilst most women were encouraged by the high accuracy
rates associated with NIPT, the small false positive and
negative rates were the reason why three high-risk women
opted for invasive testing.
“I think the tricky thing for me is how it’s used at the
moment and so therefore in the context of how I
decided to use it myself in decision-making as to
invasive testing or not. Because I think largely, at the
moment, although it is very sensitive and speciﬁc, it is
seen as a screening test rather than a deﬁnitive test.”
P80: high risk, had NIPT.
Personal experiences and reﬂections on coping
Women’s perceptions of whether they felt physically and
mentally able to take on the challenges of caring for a child
with Down syndrome were found to play a signiﬁcant role in
inﬂuencing their attitudes towards undergoing NIPT. During
these considerations, some reﬂected on the extent to which
they perceived themselves to be at risk as a result of their
age, for example, ‘I’m anxious about Down’s [syndrome] with
the risk at my age’. Some also considered their current care
responsibilities including children and partners, current health
issues, and what it would mean to care for a child with the
condition in the context of their families’ lives at that particular
time as highlighted by the following quote:
“I think, for me, in particular, my husband has multiple
sclerosis and I’ve got two children already and I’m a
bit older and so it was very important for me… I was
quite clear about the fact that I couldn’t take on caring
for something knowing that I might have to care for my
husband in the future.” P21: intermediate risk, had
NIPT
Another woman who had declined screening in her ﬁrst
pregnancy because she felt she could ‘take on the world’, then
opted for screening and NIPT in her second pregnancy as her
views about raising a child with disabilities had changed
signiﬁcantly:
“Second time round it felt like we weren’t 100% sure
that we would necessarily go through with having a
child who had disabilities…and that’s partly linked to
our older son who was very ill between 18months
and two and a half and I think that made us realise
quite how enormous having a very ill child is
emotionally and in terms of how that affects your life.”
P15: intermediate risk, had NIPT
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These examples highlight how past experiences can play a
signiﬁcant role in the way people think about the future, and
the level of uncertainty they are prepared to accept,
irrespective of their particular demographic risk.
Participants also reﬂected on their ‘future lives’, for
example, one participant with a high-risk reﬂected on what
the long term future of parenting a child affected by Down
syndrome would look like and the implications for her
own children.
“It’s not just thinking about the here and now…When
you think your average child sort of 18/19/20 is
really sort of, pretty independent….we would never
have that. We would have still had a very dependent
child that needed us. That has really played a
decision.” P44: high risk, had NIPT and invasive
testing
Moral or religious values
Moral or religious views around termination of pregnancy
and perceived quality of life of a child with Down
syndrome (or Edwards or Patau) were frequently cited when
women reﬂected on their attitudes towards NIPT. The vast
majority of women did not have any moral or religious
objections to termination per se. Thus, they considered the
quality of life of that child, and whether the condition was
severe enough to warrant termination of pregnancy. Most
women agreed that the quality of life of a child with
Edwards or Patau was so poor that it did justify termination
of pregnancy.
“If it was Down syndrome I would want to know so that
I could prepare myself…If it was something like
Edwards syndrome or something where the quality of
life is pretty horrendous and the baby wouldn’t live
particularly long I think it would be too upsetting for
everybody and I’d probably want to end it.” P11:
intermediate risk, had NIPT
For a small number of women, however, termination
was considered unacceptable, irrespective of what the
condition was.
Interviewer ‘Would termination be an option for you?’
Interviewee ‘No, for me it’s not an option. You must have
what God give(s) you.’ P34, intermediate
risk, declined NIPT
Nevertheless, the vast majority of women who had moral or
religious objections to termination of pregnancy still had a
positive attitude towards NIPT, because it gave women
reproductive autonomy and enabled them to prepare for the
birth of the child.
“The beneﬁt I think would be the fact that yes we can
be prepared for it. We can ﬁnd out more information
on Down’s Syndrome and plan ahead” P14,
intermediate risk, had positive NIPT result, declined
invasive testing and continued pregnancy
Ambivalence towards undergoing NIPT
In a small number of cases, it became apparent that there
were mixed feelings or ambivalence towards undergoing
NIPT. In these cases, the decision regarding NIPT uptake
was less clear-cut, with arguments both for and against
testing. One woman spoke of her desire for information
about the health of the baby, but at the same time
acknowledged the potential for additional anxiety whilst
waiting two weeks for the test results. Another woman
acknowledged concerns around ‘over-testing’ in pregnancy,
yet found it difﬁcult to ‘decline a test that was offered by
trusted health professionals’. These examples demonstrate
that there are likely to be women for whom decisions around
NIPT are particularly challenging, and who may need
additional support during decision-making.
Deliberation
A key ﬁnding from our analysis was that, for many
participants, decision-making was a multistep process. The
initial consideration occurred when they ﬁrst encountered
NIPT at the booking-in appointment. These women made
an initial judgement about whether NIPT was relevant to
them but were not yet required to make a decision until
they received the DS screening result and were considered
eligible for the study. The way that the study was
conducted, with multiple points at which to consider NIPT,
was found to facilitate this process, as highlighted in the
following quote:
“We had plenty of time because it was discussed at
several different points so that was absolutely ﬁne.”
P18: intermediate risk, had NIPT
This multistep deliberative process was not evident in all
cases. In a number of cases, women commented that they
did not give NIPT much consideration early on in the process
as it was not yet fully relevant to them. It was only once they
found to have a risk >1/1000 that the decision became
relevant.
“The ﬁrst I heard about [NIPT] was when they sent all
the information about my booking in appointment…
And at the time I read it, but I dismissed it because I
thought oh I won’t be in that group… so I’d heard
about it then but then I didn’t really consider it until I
actually went for my [NIPT] test and got the results.”
P15: intermediate risk, had NIPT
In another example, the majority of the deliberative process
was focused on decision-making around DSS, and NIPT was
seen as an extension of this decision. This woman described
her decision about NIPT as being ‘a no-brainer’ with the ‘only
difﬁculty being the initial decision about whether to have
screening done.’
In a small number of cases, it was less clear as to whether
participants had given sufﬁcient deliberation to NIPT. For
example, one woman described NIPT as being a routine test
– ‘It’s something that you do…’and had not considered the
potential outcomes. The potential for routinisation of testing
was evident in another comment from one woman who
described NIPT as ‘just another blood test so there wasn’t
much to think about’. These comments underscore the
complexity of ensuring informed decision-making when a
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new technology is masked behind a seemingly old technology –
a blood test.
DISCUSSION
As far as we are aware, this is the ﬁrst study to use a
qualitative approach to look at the multiple components
of informed choice in the context of NIPT. Research into
informed decision-making for NIPT is now beginning to
emerge;20,21however, these have predominantly been
quantitative in scope. The ﬁndings from this study must
be viewed with some degree of caution given that NIPT is
unlikely to be offered in clinical practice with the same
emphasis on written information and lengthy pre-test
counselling as was provided in this pilot study.
Nevertheless, our study has revealed the complexities of
the decision-making process whereby participants
frequently used a combination of clinical information,
personal experiences and moral values to guide action.
Moreover, we observed a deliberative process in which
there may be multiple steps to deciding whether to accept
or decline NIPT. This concurs with most health behaviour
theories which consider health decisions to be the end
result of a decision-making process that is based on
deliberative processing of the available information.22–24
Women’s initial unfamiliarity with NIPT, coupled with an
increased risk result, may have led them to think through
the decision more consciously and ﬁnd more relevance in
the decision that led to them becoming more informed, a
key aspect of Adult Learning Theory, whereby individuals
explore the basis for assumptions and reframe preconceptions
in the presence of new information.25 Re-examining informed
choice once NIPT is offered routinely in clinical care would be
important to ensure rates of informed choice remain high.
Reﬂections on personal experiences, coping, quality of life
and views towards termination were identiﬁed as dominant
factors when women formulated their attitudes towards
NIPT. These reﬂections were considered in conjunction with
the clinical information provided by the health professional.
These ﬁndings chime with our previous research on NIPT26
where quality of life, coping and beliefs around termination
of pregnancy were identiﬁed as important factors when
making decisions around prenatal testing. Other studies
looking at decision-making for both DS screening and
invasive testing have identiﬁed similar ﬁndings.27–29 This
suggests that the experience of decision-making around NIPT
is not signiﬁcantly different from other types of prenatal tests
where personal experiences are key factors. Nevertheless, it
could be argued that the decision-making process is easier
because women do not also have to consider these factors
against the risk of miscarriage.
One aspect where women had less knowledge was with
regard to DS itself. Archibald and McClaren highlight the
importance of incorporating the role of experiential
knowledge into the development of educational materials
and genetic counselling approaches.30 This could include
providing insight into the ‘lived experience’ of the condition
through vignettes or videos of people with the condition
and their families, and thereby potentially improve
understanding of DS.
In general, women were judged to have sufﬁcient
knowledge about the test and testing procedure to enable
them to make an informed decision about NIPT.
Nevertheless, comments such as understanding fetal
material to originate from the baby (it originates from
placental trophoblasts) and the high accuracy rate enabling
women to be ‘almost sure’ and that there was a 1% chance
the result could be incorrect (positive predictive value for
NIPT has been shown to be as low as 50% for NIPT)31 does
indicate that some of the limitations of the technology may
not have been fully comprehended. These ﬁndings highlight
the need for health professionals to have a good
understanding of the limitations of NIPT and be aware that
women may come with pre-existing views that have been
inﬂuenced by the media32 or commercial NIPT providers33
and misconceptions and misunderstanding may need to be
addressed.
Women were found to not only have sufﬁcient knowledge
of the test and an attitude reﬂected in their decision
regarding NIPT but also had the opportunity to consider
the implications of the test results. This is consistent with
our quantitative ﬁndings where rates of informed choice
were high with most women having deliberated on the
decision.15 This emphasizes the importance of allowing
women’s time to have this reﬂective dialogue.
Implementation of NIPT as a contingent test is one way that
this deliberative process may be facilitated as decisions can
be made in a stepwise manner. Nevertheless, NIPT in clinical
service is likely to be offered very differently with much less
time dedicated to pre-test counselling and explanation of
the different options available. Whether women will have
adequate time to make decisions in a stepwise manner
remains to be seen and should form the basis of further
research when NIPT is introduced into routine practice.
Our ﬁndings also demonstrate the different paths women
take when making decisions about NIPT and the possibility
for ambivalence around testing. It is imperative that health
professionals support women not only by ensuring they have
sufﬁcient knowledge about NIPT but also through facilitating
a dialogue whereby women and partners reﬂect on the
implications of the test results guided by individual values
and preferences.
STUDY LIMITATIONS
A key limitation of this study is that the women received
extensive written and verbal information from a dedicated
research midwife, which may not to reﬂect the reality of
how NIPT will be offered in a routine clinical practice.
Furthermore, the population were highly educated and well
informed. Understanding some of the complexities
associated with NIPT may be more challenging for people
with lesser levels of education or lower literacy in English.
The majority of women in this study accepted NIPT and
may therefore be more likely to hold positive attitudes
towards NIPT than women who declined. This may have
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positively skewed our ﬁndings. Of note, a number of women
(n = 13) who had NIPT and received a diagnosis of DS chose
to continue the pregnancy, supporting the observation that
women with a positive attitude towards NIPT may use it to
prepare for the birth of a child with DS.18
CONCLUSION
Our study has highlighted the multiple factors that inﬂuence
women’s attitudes towards testing including how NIPT
compares with alternative prenatal testing options,
reﬂections on coping, personal experiences and
circumstances, quality of life and attitudes towards
termination of pregnancy. As the diagnostic capabilities of
NIPT increase, there will be new challenges to address in
order to prepare pregnant women to make informed choices.
Ensuring healthcare providers who are providing pre-test
counselling are aware of the myriad of factors that inﬂuence
decision-making and the different ways in which women
perceive and respond to these factors is critical.
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WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Non-invasive prenatal testing (NIPT) for aneuploidies has entered
clinical practice, although concerns exist around the potential for
routinisation and erosion of informed choice.
• Research into informed decision-making for NIPT is now
beginning to emerge, although these are predominantly
quantitative studies.
WHAT DOES THIS STUDY ADD?
• Participants frequently used a combination of clinical information,
personal experiences and moral values to guide action.
• For many participants, decision-making was a multistep deliberative
process which occurred as and when new information became
available.
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